PURPOSE: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved as maintenance therapy for patients with advanced pancreatic cancer (PC) and a germline BRCA1 or BRCA2 pathogenic variant (PV). This investigator-initiated, single-arm phase II study assessed the role of the PARPi rucaparib as maintenance therapy in advanced PC with germline or somatic PV in BRCA1, BRCA2, or PALB2. PATIENTS AND METHODS: Eligible patients had advanced PC; germline (g) or somatic (s) PVs in BRCA1, BRCA2, or PALB2, and received at least 16 weeks of platinum-based chemotherapy without evidence of platinum resistance. Chemotherapy was discontinued and patients received rucaparib 600 mg orally twice a day until progression. The primary end point was the progression-free survival (PFS) rate at 6 months (PFS6). Secondary end points included safety, ORR, disease control rate, duration of response, and overall survival. RESULTS: Of 46 enrolled patients, 42 were evaluable (27 gBRCA2, seven gBRCA1, six gPALB2, and two sBRCA2). PFS6 was 59.5% (95% CI, 44.6 to 74.4), median PFS was 13.1 months (95% CI, 4.4 to 21.8), and median overall survival was 23.5 months (95% CI, 20 to 27). The PFS at 12 months was 54.8%. ORR of the 36 patients with measurable disease was 41.7% (3 complete responses; 12 partial responses; 95% CI, 25.5 to 59.2), and disease control rate was 66.7% (95% CI, 49.0 to 81.4). Median duration of response was 17.3 months (95% CI, 8.8 to 25.8). Responses occurred in patients with gBRCA2 (41%, 11 out of 27), gPALB2 (50%, 3 out of 6), and sBRCA2 (50%, 1 out of 2). No new safety signals were noted. CONCLUSION: Maintenance rucaparib is a safe and effective therapy for platinum-sensitive, advanced PC with a PV in BRCA1, BRCA2, or PALB2. The finding of efficacy in patients with gPALB2 and sBRCA2 PVs expands the population likely to benefit from PARPi beyond gBRCA1/2 PV carriers.
PURPOSE: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved as maintenance therapy for patients with advanced pancreatic cancer (PC) and a germline BRCA1 or BRCA2 pathogenic variant (PV). This investigator-initiated, single-arm phase II study assessed the role of the PARPi rucaparib as maintenance therapy in advanced PC with germline or somatic PV in BRCA1, BRCA2, or PALB2. PATIENTS AND METHODS: Eligible patients had advanced PC; germline (g) or somatic (s) PVs in BRCA1, BRCA2, or PALB2, and received at least 16 weeks of platinum-based chemotherapy without evidence of platinum resistance. Chemotherapy was discontinued and patients received rucaparib 600 mg orally twice a day until progression. The primary end point was the progression-free survival (PFS) rate at 6 months (PFS6). Secondary end points included safety, ORR, disease control rate, duration of response, and overall survival. RESULTS: Of 46 enrolled patients, 42 were evaluable (27 gBRCA2, seven gBRCA1, six gPALB2, and two sBRCA2). PFS6 was 59.5% (95% CI, 44.6 to 74.4), median PFS was 13.1 months (95% CI, 4.4 to 21.8), and median overall survival was 23.5 months (95% CI, 20 to 27). The PFS at 12 months was 54.8%. ORR of the 36 patients with measurable disease was 41.7% (3 complete responses; 12 partial responses; 95% CI, 25.5 to 59.2), and disease control rate was 66.7% (95% CI, 49.0 to 81.4). Median duration of response was 17.3 months (95% CI, 8.8 to 25.8). Responses occurred in patients with gBRCA2 (41%, 11 out of 27), gPALB2 (50%, 3 out of 6), and sBRCA2 (50%, 1 out of 2). No new safety signals were noted. CONCLUSION: Maintenance rucaparib is a safe and effective therapy for platinum-sensitive, advanced PC with a PV in BRCA1, BRCA2, or PALB2. The finding of efficacy in patients with gPALB2 and sBRCA2 PVs expands the population likely to benefit from PARPi beyond gBRCA1/2 PV carriers.
Authors: Douglas Rubinson; Brian M Wolpin; Ilana S Warsofsky; David P Ryan; Kimberly Perez; Osama Rahma; Harshabad Singh; Matthew B Yurgelun; Geoffrey I Shapiro; Andrew J Aguirre; Alan D D'Andrea; James M Cleary Journal: J Gastrointest Oncol Date: 2021-12
Authors: Kim A Reiss; Rosemarie Mick; Ursina Teitelbaum; Mark O'Hara; Charles Schneider; Ryan Massa; Thomas Karasic; Rashmi Tondon; Chioma Onyiah; Mary Kate Gosselin; Alyssa Donze; Susan M Domchek; Robert H Vonderheide Journal: Lancet Oncol Date: 2022-07-07 Impact factor: 54.433
Authors: Adam Ofri; Danika Zuidersma; Connie I Diakos; Amanda Stevanovic; Matthew Wong; Samriti Sood; Jaswinder S Samra; Anthony J Gill; Anubhav Mittal Journal: Front Surg Date: 2022-06-24
Authors: E Gabriela Chiorean; Katherine A Guthrie; Philip A Philip; Elizabeth M Swisher; Florencia Jalikis; Michael J Pishvaian; Jordan Berlin; Marcus S Noel; Jennifer M Suga; Ignacio Garrido-Laguna; Dana Backlund Cardin; Marc R Radke; Mai Duong; Shay Bellasea; Andrew M Lowy; Howard S Hochster Journal: Clin Cancer Res Date: 2021-09-27 Impact factor: 13.801
Authors: James M Cleary; Brian M Wolpin; Stephanie K Dougan; Srivatsan Raghavan; Harshabad Singh; Brandon Huffman; Nilay S Sethi; Jonathan A Nowak; Geoffrey I Shapiro; Andrew J Aguirre; Alan D D'Andrea Journal: Clin Cancer Res Date: 2021-07-20 Impact factor: 13.801
Authors: Parisa Momtaz; Catherine A O'Connor; Joanne F Chou; Marinela Capanu; Wungki Park; Chaitanya Bandlamudi; Michael F Berger; David P Kelsen; Sarah P Suehnholz; Debyani Chakravarty; Kenneth H Yu; Anna M Varghese; Alice Zervoudakis; Jia Li; Geoffrey Y Ku; Jennifer S Park; Marina Shcherba; James J Harding; Zoe Goldberg; Ghassan K Abou-Alfa; Erin E Salo-Mullen; Zsofia K Stadler; Christine A Iacobuzio-Donahue; Eileen M O'Reilly Journal: Cancer Date: 2021-08-05 Impact factor: 6.921